GLP-1 medications are FDA-approved treatments that help patients manage obesity and reduce the risk of serious chronic diseases including type 2 diabetes, heart disease, hypertension, and sleep apnea. These treatments have helped thousands of patients improve their health, quality of life, and long-term outcomes.

Now, proposed coverage cuts could limit access to these life-changing medications for Group Insurance Commission (GIC) and MassHealth patients across Massachusetts.

Obesity is a chronic disease — not a personal failure — and patients deserve access to evidence-based care. Eliminating coverage would disproportionately impact lower-income residents and public employees while increasing long-term healthcare costs associated with untreated obesity and related conditions.

Massachusetts has long been a leader in healthcare innovation and equitable care. We urge lawmakers to protect patient access to medically necessary obesity treatment by supporting Amendment 1693.

Take action today by sending a message to your legislators and urging them to preserve GLP-1 obesity treatment coverage for Massachusetts patients.